Dose-sparing effect of Sabin-derived inactivated polio vaccine produced in Japan by intradermal injection device for rats

• Published in: Biologicals Vol. 82; p. 101677
• Main Authors: Itoh, Eriko, Shimizu, Sakiko, Ami, Yasushi, Iwase, Yoichiro, Someya, Yuichi
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.05.2023
• Subjects: Dose-sparing; Inactivated poliovirus vaccine; Intradermal injection device; Sabin virus; Inactivated poliovirus vaccine; Intradermal injection device; Sabin virus; Dose-sparing
• ISSN: 1045-1056; 1095-8320
• DOI: 10.1016/j.biologicals.2023.101677

The live-attenuated oral polio vaccine has long been used as the standard for polio prevention, but in order to minimize the emergence of pathogenic revertants, the inactivated polio vaccine (IPV), which is administered intramuscularly or subcutaneously, is being increasingly demanded worldwide. However, there is a global shortage of IPV, and its cost is an obstacle in developing countries. Therefore, dose-sparing with intradermal administration of IPV has been investigated. In this study, rats were immunized by intradermal (ID) and intramuscular (IM) administration of Sabin-derived inactivated polio vaccine (sIPV) produced in Japan, and the immune responses were evaluated. The results showed that one-fifth (1/5)-dose of ID administration yielded neutralizing antibody titers comparable to the full-dose IM administration, whereas 1/5-dose of IM administration was less effective than the full dose. Furthermore, a vertical puncture-type ID injection device (Immucise) that was originally developed for humans was modified for rats, resulting in successful and stable ID administration into the thin skin of rats. Based on these results, the ID administration of sIPV using Immucise in clinical use is expected to offer benefits such as reduced amounts of vaccine per dose, cost-effectiveness, and thereby the feasibility of vaccination for more people.